Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01440517 · ClinicalTrials.gov registry record · Phase 2
Results of Tc99m-Maraciclatide Scintigraphy in Subjects With Diabetes Mellitus and Heart Failure With Preserved Left Ventricular Ejection Fraction
A Phase 2 study, sponsored by GE Healthcare.
- Terminated
- Registry status
- Phase 2
- Development phase
- 4
- Enrollment target
NCT01440517 is a Phase 2 study that was terminated before completion, run by GE Healthcare. The registered enrollment target is 4 participants.
The verdict
NCT01440517, a Phase 2 study, was terminated before completion, sponsored by GE Healthcare.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 4 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the results of 99mTc maraciclatide scintigraphy in diabetic subjects with HFPEF. A maximum of 20 subjects with Diabetes Mellitus (DM) and Heart Failure With Preserved Left Ventricular Ejection Fraction (HFPEF) will be enrolled and imaged with 99mTc maraciclatide. In addition, a maximum of 10 subjects with DM and diastolic dysfunction but no diagnosis of heart failure (HF) will be enrolled and imaged with 99mTc-maraciclatide.
Interventions
- DRUG Tc99m-Maraciclatide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4 participants |
| Start Date | 2011-08 |
| Est. Completion | 2012-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01440517
The ClinicalTrials.gov registry entry for NCT01440517 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 4 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GE Healthcare, which has 99 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Tc99m-Maraciclatide is the first listed.
NCT01440517 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01440517 about?
NCT01440517 is a clinical study titled "Results of Tc99m-Maraciclatide Scintigraphy in Subjects With Diabetes Mellitus and Heart Failure With Preserved Left Ventricular Ejection Fraction". The purpose of this study is to evaluate the results of 99mTc maraciclatide scintigraphy in diabetic subjects with HFPEF. A maximum of 20 subjects with Diabetes Mellitus (DM) and Heart Failure With Preserved Left Ventricular Ejection Fraction (HFPEF) will be enrolled and imaged with 99mTc maraciclat...
What is the current status of trial NCT01440517?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 4 participants. The study started on 2011-08. Estimated completion is 2012-03.
What interventions are being tested in trial NCT01440517?
The interventions under investigation include: Tc99m-Maraciclatide (DRUG).
Who is sponsoring clinical trial NCT01440517?
This trial is sponsored by GE Healthcare, which has 99 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.